Page 42 - 77_04

MEDICAMENTA
NON
MELLA…

7. Rothwell,
P.
M.,
Fowkes,
G.
R.,
Belch,
J.
F.,
Ogawa,
H.,
Warlow,
Ch.
P.,
&
Meade,
T.
W.
(2010).

Effect
of
daily
aspirin
on
long-­-term
risk
of
death
due
to
cancer:
analysis
of
individual
patient

data
from
randomised
trials.
The
Lancet,
377,
31-­-41.

8. Shaughnessy,
A.
F.
(2011).
Old
drugs,
new
tricks.
British
Medical
Journal,
9,
342,
d741.

9. Healy,
D.
(2004).

The
creation
of
Psychopharmacology.
Harvard
University
Press,
pág.
37-­-73.

10.
Boyer,
E.
W.,
&
Shannon,
M.
(2005).
The
serotonin
syndrome.
New
England
Journal
of

Medicine,
352
,
1112–20.

11.
Rees,
L.
(1960).
Chlorpromazine
and
allied
phenothiazine
derivatives.
British
Medical
Journal,

2,
522–225.

12.
Leucht,
S.,
Corves,
C.,
Arbter,
D.,
Engel,
R.
R.,
Li,
Ch.,
&
Davis,
J.
M.
(2009).
Second-­-generation

versus
first-­-generation
antipsychotic
drugs
for
schizophrenia:
a
meta-­-analysis.
The
Lancet,

373,
31-­-41.

13.
Szarfman,
A.,
Tonning,
J.,
Levine,
J.,
&
Doraiswamy,
P.
(2006).
Atypical
antipsychotics
and

pituitary
tumors:
a
pharmacovigilance
study.
Pharmacotherapy,
26,
748-­-758.

14.
Lieberman,
J.
A.,
Stroup,
T.
S.,
McEvoy,
J.
P.,
Swartz,
M.
S.,
Rosenheck,
R.
A.,
Perkins,
D.
O.,
Keefe,

R.
S.
E.,
Davis,
S.
M.,
Davis,
C.
E.,
Lebowitz,
B.
D.,
Severe,
J.,
&
Hsiao,
J.
K.
(2005).
Effectiveness
of

Antipsychotic
Drugs
in
Patients
with
Chronic
Schizophrenia.
New
England
Journal
of
Medicine,

353,
1209
-­-1223.

15.
Rakesh,
J.
(2004).
Single-­-Action
Versus
Dual-­-Action
Antidepressants,
Journal
of
Clinical

Psichiatry,
6,
7-­-11.

16.
Deininger,
M.
W.,
&
Druker,
B.
J.
(2003).
Specific
targeted
therapy
of
chronic
myelogenous

leukemia
with
imatinib.
Pharmacological
Reviews,
55,
401–23.

17.
Manley,
P.
W.,
Cowan-­-Jacob,
S.
W.,
&
Mestan,
J.
(2005).
Advances
in
the
structural
biology,

design
and
clinical
development
of
Bcr-­-Abl
kinase
inhibitors
for
the
treatment
of
chronic

myeloid
leukaemia.
Biochimica
et
Biophysica
Acta,
1754,
3-­-13.

18.
Druker,
B.
J.,
&
Lydon,
N.
B.
(2000).
Lessons
learned
from
the
development
of
an
Abl
tyrosine

kinase
inhibitor
for
chronic
myelogenous
leucemia,
Journal
of
Clinical
Investigation,
105,
3-­-7.

19.
Guilhot,
F.
(2004).
Indications
for
Imatinib
Mesylate
Therapy
and
Clinical
Management.
The

Oncologist,
9,
271–281.

20.
Hirota,
S.,
Isozaki,
K.,
Moriyama,
Y.,
Hashomoto,
K.,
Nishida,
T.,
Ishoguro,
S.,
Kawano,
K.,

Hanada,
M.,
Kurata,
A.,
Takeda,
M.,
Muhammad
Tunio,
G.,
Matsuzawa,
Y.,
Kanakura,
Y.,

Shinomura,
Y.,
&
Kitamura,
Y.
(1998).
Gain-­-of-­-function
mutations
of
c-­-kit
in
human

gastrointestinal
stromal
tumors.
Science,
279:
577-­-80.

21.
Jonson,
D.
S.,
&
Li,
J.
J.
(2007).
The
art
of
Drug
Synthesis,
Wiley-­-Interscience.

22.
Davignon,
J.,
&
Laaksonen,
R.
(1999).
Low-­-density
lypoprotein
independent
effects
of
statins.

Current
Opinion
in
Lipidology,
10,
543-­-559.

23.
Singh,
V.,
&
Deedwania,
P.
(2008).
Expanding
roles
for
atorvastatin.
Drugs
of
Today,
44,
455-­-
471.

24.
Aviram,
M.,
Dankner,
G.,
Cogan,
U.,
Hochgraf,
E.,
&
Brook,
J.
G.
(1992).
Lovastatin
inhibits
LDL

oxidation
and
alters
its
fluidity
and
uptake
by
macrophages:
in
vitro
and
in
vivo
studies.

Metabolism,
41,
229-­-235.

25.
Toschi,
V.,
Gallo,
R.,
Lettino,
M.,
Fallon,
J.
T.,
Gertz,
S.,
Fernández-­-Ortiz,
A.,
Chesebro,
J.
H.,

Badimon,
L.,
Nemerson,
Y.,
Fuster,
V.,
&
Badimon,
J.
J.
(1997).
Tissue
factor
modulates
the

thrombogenicity
of
human
atherosclerotic
plaque.
Circulation,
95,
594-­-599.

26.
Hernández-­-Perera,
O.,
Pérez-­-Sala,
D.,
Navarro-­-Antolín,
J.,
Sánchez-­-Pascuala,
R.,
Hernández,
G.,

Díaz,
C.,
&
Lamas,
S.
(1998).
Effects
of
the
3-­-hydroxy-­-3-­-methylglutaryl-­-CoA
reductase

inhibitors,
atorvastatin
and
simvastatin,
on
the
expression
of
endothelin-­-1
and
endotelial
nitric

oxide
synthase
in
vascular
endotelial
cells.
Journal
of
Clinical
Investigation,
101,
2711-­-2719.

73